Law & Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Law & Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Cancer
SuperGens MP-470 Demonstrates Clinical Tumor Regression When Combined with Standard of Care Chemotherapy
November 15th, 2008
SuperGen, Inc. (NASDAQ: SUPG), a pharmaceutical company dedicated to the discovery and development of novel cancer therapies, presented data on MP-470, its lead product candidate, and four additional posters, at the 20th EORTC-NCI-AACR Symposium on "Molecular Targets and Cancer Therapeutics" in Geneva, Switzerland. MP-470, an orally bio-available multi-targeted tyrosine kinase inhibitor, showed encouraging tumor regression results in the first two arms (paclitaxel/carboplatin and carboplatin/etoposide) of its current Phase 1b clinical trial examining MP-470 combined with five standard of care (SOC) anticancer treatments. "We are extremely pleased to report a series of...
Source: Law & Health Weekly (2008-11-15)
|
